NeOnc Technologies Holdings, Inc. NTHI
3.00 USD -0.17 (-5.36%)
Nov 5, 2026, 9:44 AM EST
2.96 Day range 3.12
2.50 52-week range 12.00
- YTD
- -63.72%
- 1 year
- -71.40%
- Market cap
- 86.42M
- Revenue (ttm)
- 70.46K
- EPS (ttm)
- -2.13
- Shares out
- 22.56M
- YTD return
- -63.72%
- 1-year return
- -71.40%
- Volume
- 11.64K
- Avg volume
- 211.73K
- Open
- 3.12
- Previous close
- 3.17
- Day's range
- 2.96 – 3.12
- 52-week range
- 2.50 – 12.00
1M +0.25 (+8.56%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -100.00%
- Free cash flow
- 1.21M
- Total cash
- 31.86K
- Total debt
- 6.61M
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 0.00
- 200-day average
- 0.00
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
NTHI Revenue — quarterly 0
NTHI Net income — quarterly -14.24M
NTHI EPS — quarterly -0.58
About NeOnc Technologies Holdings, Inc.
Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.
- Country
- United States
- Website
- neonctech.com
News
NeOnc Is Putting Two Brain Cancer Programs on the Global Stage 
NeOnc Technologies To Present Data From Intranasal NEO100 And Oral NEO212 Programs In Two Posters, At 31st Annual Meeting And Education Day Of SNO 
NeOnc Technologies to Present Data from Its NEO100 and NEO212 Programs at the 31st Annual Meeting of the Society for Neuro-Oncology 
NeOnc's Ambitious Brain Cancer Plans are Setting the Stage 
12 Health Care Stocks Moving In Friday's Intraday Session 
NeOnc Technologies Signs MoU With Abu Dhabi's Health Department Over Development Research And Clinical Capability In Oncology, Centrla Nervous System Therapeutics 
Alpha Buying: 4 Biotech Stocks Insiders Are Betting On 
NeOnc Technologies Schedules FDA In-Person End-of-Phase 1 Type B Meeting Concerning NEO212 For November 17 - Roth Capital Initiates Coverage On NeOnc Technologies Hldgs with Buy Rating, Announces Price Target of $20
- NeOnc Announces Executive Chairman, President And CEO Amir Heshmatpour Purchases Additional 35K Of Company Shares For ~$115,400, At Weighted Average Price Of ~$3.30/Shr
Your note
Sign in to keep a note on NTHI — it syncs with the Stock Master app.